TP53 and neoplasm: Optimized peri-operative strategies can blunt the early inflammatory spike and accelerate immune recovery, reinforcing our observation that durable reductions in p53, NY-ESO-1, and related autoantibodies are most evident once the pro-inflammatory milieu has subsided and effective tumor immunity is re-established [27].